Pharsight

1. List of Abilify Mycite Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507	OTSUKA	Communication system with enhanced partial power source and method of manufacturing same	Jun, 2032 (9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. List of Abraxane drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393318	ABRAXIS BIOSCIENCE	Methods of treating cancer	Mar, 2032 (9 years from now)
US9597409	ABRAXIS BIOSCIENCE	Methods of treating cancer	Mar, 2032 (9 years from now)
US9393318 (Pediatric)	ABRAXIS BIOSCIENCE	Methods of treating cancer	Sep, 2032 (9 years from now)
US9597409 (Pediatric)	ABRAXIS BIOSCIENCE	Methods of treating cancer	Sep, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
M	Dec 6, 2022
Pediatric Exclusivity (PED)	Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/vial	11 Dec, 2015	1		27 Oct, 2024

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

3. List of Acetadote drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738	CUMBERLAND PHARMS	Acetycysteine compositions and methods of use thereof	Apr, 2032 (9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg/mL, 30 mL vials	04 Apr, 2012	3	07 Nov, 2012	21 May, 2026	Eligible

Strength	Dosage	Availability
6GM/30ML (200MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

4. List of Adzenys Er drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265737	NEOS THERAPS INC	Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)
US9017731	NEOS THERAPS INC	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)
US8709491	NEOS THERAPS INC	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 1.25MG BASE/ML	SUSPENSION, EXTENDED RELEASE;ORAL	Discontinued

5. List of Adzenys Xr-odt drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731	NEOS THERAPS	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)
US9265737	NEOS THERAPS	Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)
US8709491	NEOS THERAPS	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	10 May, 2016	1		28 Jan, 2032

Strength	Dosage	Availability
EQ 3.1MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 6.3MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 9.4MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 12.5MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 15.7MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 18.8MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription

6. List of Airduo Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (8 years from now)
US8978966	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (8 years from now)
US8714149	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2032 (9 years from now)
US10561808 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jul, 2032 (9 years from now)
US8978966 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jul, 2032 (9 years from now)
US8714149 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

7. List of Akynzeo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11312698	HELSINN HLTHCARE	Fosnetupitant chloride hydrochloride having improved stability	May, 2032 (9 years from now)
US10717721	HELSINN HLTHCARE	Substituted piperaziniums for the treatment of emesis	May, 2032 (9 years from now)
US8426450	HELSINN HLTHCARE	Substituted 4-phenyl pyridines having anti-emetic effect	May, 2032 (9 years from now)
US9908907	HELSINN HLTHCARE	Substituted piperaziniums for the treatment of emesis	May, 2032 (9 years from now)
US9403772	HELSINN HLTHCARE	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator	May, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895586	HELSINN HLTHCARE	Methods of treating emesis	May, 2032 (9 years from now)
US10208073	HELSINN HLTHCARE	Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator	May, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
235 mg/0.25 mg per 20 mL	19 Apr, 2022	1		02 Jun, 2037

Strength	Dosage	Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

8. List of Alecensa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514	HOFFMANN-LA ROCHE	Composition comprising tetracyclic compound	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg	11 Dec, 2019	1		04 Mar, 2032

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

9. List of Aliqopa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10383876	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts	Mar, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 14, 2022
Orphan Drug Exclusivity (ODE)	Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

10. List of Alkindi Sprinkle drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740	ETON	Treatment of adrenal insufficiency	Nov, 2032 (9 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
0.5MG	GRANULE;ORAL	Prescription
1MG	GRANULE;ORAL	Prescription
2MG	GRANULE;ORAL	Prescription
5MG	GRANULE;ORAL	Prescription

11. List of Amvuttra drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10570391	ALNYLAM PHARMS INC	RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases	Nov, 2032 (9 years from now)
US9399775	ALNYLAM PHARMS INC	RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases	Nov, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
25MG/0.5ML (25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

12. List of Aptiom drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747	SUNOVION PHARMS INC	Treatments involving eslicarbazepine acetate or eslicarbazepine	Aug, 2032 (9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg, 400 mg, 600 mg and 800 mg	08 Nov, 2017	7	29 Jun, 2021	24 Aug, 2032	Deferred

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
400MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription
800MG	TABLET;ORAL	Prescription

13. List of Aristada drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458	ALKERMES INC	Pharmaceutical compositions comprising sorbitan esters	Mar, 2032 (9 years from now)
US9034867	ALKERMES INC	Pharmaceutical compositions comprising sorbitan esters	Nov, 2032 (9 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

14. List of Armonair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (8 years from now)
US8978966	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (8 years from now)
US8714149	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2032 (9 years from now)
US10561808 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jul, 2032 (9 years from now)
US8978966 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jul, 2032 (9 years from now)
US8714149 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 9, 2024
New Strength (NS)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

15. List of Avycaz drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9284314	ALLERGAN	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	Jun, 2032 (9 years from now)
US9695122	ALLERGAN	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	Jun, 2032 (9 years from now)
US8969566	ALLERGAN	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	Jun, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN)	Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.5GM BASE;2GM/VIAL	POWDER;INTRAVENOUS	Prescription

16. List of Azstarys drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928	COMMAVE THERAP	Methylphenidate-oxoacid conjugates, processes of making and using the same	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 5.2MG BASE;EQ 26.1MG BASE	CAPSULE;ORAL	Prescription
EQ 7.8MG BASE;EQ 39.2MG BASE	CAPSULE;ORAL	Prescription
EQ 10.4MG BASE;EQ 52.3MG BASE	CAPSULE;ORAL	Prescription

17. List of Belbuca drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539	BDSI	Transmucosal drug delivery devices for use in chronic pain relief	Dec, 2032 (9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
75 mcg and 150 mcg	24 Oct, 2016	1	23 Jul, 2027	Exinguished Non-Forfeiture
300 mcg, 450 mcg, 600 mcg and 750 mcg	04 Oct, 2016	1	23 Jul, 2027	Exinguished Non-Forfeiture
900 mcg	12 Sep, 2016	1	23 Jul, 2027	Exinguished Non-Forfeiture

Strength	Dosage	Availability
EQ 0.075MG BASE	FILM;BUCCAL	Prescription
EQ 0.15MG BASE	FILM;BUCCAL	Prescription
EQ 0.3MG BASE	FILM;BUCCAL	Prescription
EQ 0.45MG BASE	FILM;BUCCAL	Prescription
EQ 0.6MG BASE	FILM;BUCCAL	Prescription
EQ 0.75MG BASE	FILM;BUCCAL	Prescription
EQ 0.9MG BASE	FILM;BUCCAL	Prescription

18. List of Bijuva drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8633178	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8993549	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10052386	THERAPEUTICSMD INC	Progesterone formulations	Nov, 2032 (9 years from now)
US8987237	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11166963	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8933059	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11103513	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10806740	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US9006222	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11033626	THERAPEUTICSMD INC	Progesterone formulations having a desirable pk profile	Nov, 2032 (9 years from now)
US10675288	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US9114145	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US9114146	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8846648	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8846649	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10206932	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11103516	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8993548	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11110099	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10639375	THERAPEUTICSMD INC	Progesterone formulations	Nov, 2032 (9 years from now)
US9301920	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

19. List of Bijuva drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360	MAYNE PHARMA	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

20. List of Biktarvy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 18, 2026
New Chemical Entity Exclusivity (NCE)	Feb 7, 2023
New Patient Population (NPP)	Jun 18, 2022
M	Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

21. List of Bortezomib drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572	FRESENIUS KABI USA	Bortezomib formulations	Nov, 2032 (9 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

22. List of Braftovi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387208	ARRAY BIOPHARMA INC	Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (9 years from now)
US10258622	ARRAY BIOPHARMA INC	Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate	Nov, 2032 (9 years from now)
US9763941	ARRAY BIOPHARMA INC	Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 27, 2023
Orphan Drug Exclusivity (ODE)	Jun 27, 2025
New Indication (I)	Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Treatment of melanoma

Dosage: CAPSULE;ORAL

23. List of Bunavail drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177	BDSI	Abuse-resistant mucoadhesive devices for delivery of buprenorphine	Aug, 2032 (9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

24. List of Cabometyx drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349	EXELIXIS INC	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 17, 2028
New Indication (I)	Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

25. List of Caldolor drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710	CUMBERLAND PHARMS	Injectable ibuprofen formulation	Mar, 2032 (9 years from now)
US9072661	CUMBERLAND PHARMS	Injectable ibuprofen formulation	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
M	Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

26. List of Calquence drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors	Jul, 2032 (9 years from now)
CN106243113B	ASTRAZENECA	As A Selective Btk Inhibitor And Pyrazine	Jul, 2032 (9 years from now)
CN103889987A	ASTRAZENECA	As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide	Jul, 2032 (9 years from now)
CN106243113A	ASTRAZENECA	Imidazole As Selective Btk Inhibitors And Paradiazine	Jul, 2032 (9 years from now)
CN103889987B	ASTRAZENECA	Imidazole As Selective Btk Inhibitors And Paradiazine	Jul, 2032 (9 years from now)
EP3689878B1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP3689878A1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP2734522B1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP2734522A1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides as Btk inhibitors	Jul, 2032 (9 years from now)
US10239883	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides as BTK inhibitors	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 21, 2026
New Chemical Entity Exclusivity (NCE)	Oct 31, 2022
New Indication (I)	Nov 21, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia

Dosage: CAPSULE;ORAL

27. List of Calquence drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors	Jul, 2032 (9 years from now)
CN106243113B	ASTRAZENECA	As A Selective Btk Inhibitor And Pyrazine	Jul, 2032 (9 years from now)
CN103889987A	ASTRAZENECA	As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide	Jul, 2032 (9 years from now)
CN106243113A	ASTRAZENECA	Imidazole As Selective Btk Inhibitors And Paradiazine	Jul, 2032 (9 years from now)
CN103889987B	ASTRAZENECA	Imidazole As Selective Btk Inhibitors And Paradiazine	Jul, 2032 (9 years from now)
EP3689878B1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP3689878A1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP2734522B1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP2734522A1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides as BTK inhibitors	Jul, 2032 (9 years from now)
US9758524	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides as Btk inhibitors	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: TABLET;ORAL

28. List of Caspofungin Acetate drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407	FRESENIUS KABI USA	Caspofungin acetate formulations	Dec, 2032 (9 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

29. List of Cetylev drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747894	ARBOR PHARMS LLC	Effervescent compositions containing N-acetylcysteine	May, 2032 (9 years from now)
US9561204	ARBOR PHARMS LLC	Effervescent compositions containing N-acetylcysteine	May, 2032 (9 years from now)
US9427421	ARBOR PHARMS LLC	Effervescent compositions containing N-acetylcysteine	May, 2032 (9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 29 January, 2016

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

30. List of Cometriq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349	EXELIXIS	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (9 years from now)
US9717720	EXELIXIS	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (9 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

31. List of Contrave drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123	NALPROPION	Methods of providing weight loss therapy in patients with major depression	Jan, 2032 (8 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

32. List of Copiktra drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46621	SECURA	Processes for preparing isoquinolinones and solid forms of isoquinolinones	May, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11312718	SECURA	Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	Jan, 2032 (8 years from now)
US9840505	SECURA	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof	Jan, 2032 (8 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 24, 2023
Orphan Drug Exclusivity (ODE)	Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

33. List of Cotempla Xr-odt drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089496	NEOS THERAPS INC	Compositions comprising methylphenidate complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)
US9072680	NEOS THERAPS INC	Compositions comprising methylphenidate complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

34. List of Cycloset drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000522	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US8431155	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9700555	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9993474	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9192576	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US8613947	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9522117	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US10688094	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13 and 23; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 11, and 12; Adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24; Improvement of glycemic control in individuals with type 2 diabetes; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41, 52, and 53; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66, 75, and 76; Adjunct to diet and execrise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29, 39, and 40; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 13, and 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54 and 64; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29 and 39; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 13; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66 and 75; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41 and 52; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89, 99, and 100; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54, 64, and 65; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15, 27, and 28; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15 and 27; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77 and 87; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89 and 99; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43, 50 and 51; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1,10 and 11; Adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30, 41, and 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1 and 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30 and 41; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21 and 28; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12 and 19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43 and 50; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12, 19 and 20; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29; Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2 and 3; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4 and 5; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7, 8, and 9; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4, 5, and 6; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7 and 8; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16, 17, and 18; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13 and 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10, 11, and 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16 and 17; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13, 14, and 15; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28 and 29; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25 and 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 22, 23, and 24; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19 and 20; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19, 20, and 21; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28, 29, and 30; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27

Dosage: TABLET;ORAL

35. List of Defitelio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11085043	JAZZ PHARMS INC	Euglobulin-based method for determining the biological activity of defibrotide	Jun, 2032 (9 years from now)
US11236328	JAZZ PHARMS INC	Euglobulin-based method for determining the biological activity of defibrotide	Jun, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 30, 2023

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

Market Authorisation Date: 30 March, 2016

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct)

Dosage: SOLUTION;INTRAVENOUS

36. List of Descovy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 28, 2024
New Indication (I)	Oct 3, 2022

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: Prophylaxis of hiv-1 infection; Treatment of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET;ORAL

37. List of Detectnet drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159759	RADIOMEDIX	Pet tracer for imaging of neuroendocrine tumors	Aug, 2032 (9 years from now)
US10383961	RADIOMEDIX	PET tracer for imaging of neuroendocrine tumors	Aug, 2032 (9 years from now)
US11160888	RADIOMEDIX	PET tracer for imaging of neuroendocrine tumors	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 3, 2025
Orphan Drug Exclusivity (ODE)	Sep 3, 2027

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

38. List of Dexilant drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233103	TAKEDA PHARMS USA	Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy	Mar, 2032 (9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

39. List of Dexycu Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799642	EYEPOINT PHARMS	Dose guides for injection syringe	May, 2032 (9 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: NA

Dosage: SUSPENSION;INTRAOCULAR

40. List of Dilaudid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082	FRESENIUS KABI USA	Drug container	Apr, 2032 (9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA

Dosage: INJECTABLE;INJECTION

41. List of Duzallo drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546436	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Feb, 2032 (9 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

42. List of Epaned Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855214	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (9 years from now)
US9968553	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (9 years from now)
US8778366	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (9 years from now)
US8568747	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (9 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 13 August, 2013

Treatment: Method of treatment of heart failure; Treatment of hypertension; Method of treating left ventricular dysfunction; Method of treating hypertension; Treatment of heart failure

Dosage: FOR SOLUTION;ORAL

43. List of Epclusa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8940718	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (9 years from now)
US8575135	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (9 years from now)
US8921341	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
M	Apr 27, 2025
Pediatric Exclusivity (PED)	Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

44. List of Epsolay drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687465	GALDERMA LABS LP	Compositions for the treatment of rosacea	Nov, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older

Dosage: CREAM;TOPICAL

45. List of Evotaz drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	BRISTOL-MYERS SQUIBB	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

46. List of Evzio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2032 (9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

47. List of Evzio (autoinjector) drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2032 (9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

48. List of Fetzima drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937	ALLERGAN	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide	May, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
M	Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

49. List of Firdapse drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11268128	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US11274332	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US11274331	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US11060128	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 28, 2023
Orphan Drug Exclusivity (ODE)	Nov 28, 2025
New Patient Population (NPP)	Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

50. List of Firmagon drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415085	FERRING	Method of treating prostate cancer with GnRH antagonist	Apr, 2032 (9 years from now)
US10695398	FERRING	Method of treating prostate cancer with GnRH antagonist	Apr, 2032 (9 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

51. List of Genvoya drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

52. List of Gilenya drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592208	NOVARTIS	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	Mar, 2032 (9 years from now)
US9592208 (Pediatric)	NOVARTIS	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	Sep, 2032 (9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Market Authorisation Date: 21 September, 2010

Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

53. List of Gonitro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592	POHL BOSKAMP	Stabilized granules containing glyceryl trinitrate	Mar, 2032 (9 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Market Authorisation Date: 08 June, 2016

Treatment: NA

Dosage: POWDER;SUBLINGUAL

54. List of Harvoni drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256	GILEAD SCIENCES INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US10456414	GILEAD SCIENCES INC	Methods for treating HCV	Sep, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Dosing Schedule (D)	Nov 15, 2022
Orphan Drug Exclusivity (ODE)	Apr 7, 2024
Pediatric Exclusivity (PED)	Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

55. List of Ilevro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921337	NOVARTIS	Carboxyvinyl polymer-containing nanoparticle suspensions	Mar, 2032 (9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

56. List of Imvexxy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537581	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11246875	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11241445	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US10835487	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US9289382	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US10806697	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11351182	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11304959	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11497709	THERAPEUTICSMD INC	NA	Nov, 2032 (9 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

57. List of Inbrija drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945612	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (9 years from now)
US8685442	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (9 years from now)
US8545878	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (9 years from now)
US9393210	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (9 years from now)

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER;INHALATION

58. List of Inrebic drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391094	IMPACT	Compositions and methods for treating myelofibrosis	Jun, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 16, 2026
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

59. List of Ionsys drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8781571	THE MEDICINES CO	Switch validation circuit and method	Mar, 2032 (9 years from now)
US8428708	THE MEDICINES CO	Self-test for analgesic product	May, 2032 (9 years from now)
US8428709	THE MEDICINES CO	Current control for electrotransport drug delivery	Jun, 2032 (9 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

60. List of Isentress drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772888	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Mar, 2032 (9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

61. List of Jornay Pm drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241392	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10905652	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10182995	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US8927010	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9023389	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9283214	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9498447	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US11241391	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10881618	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10617651	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10292937	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9603809	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US8916588	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9034902	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9028868	IRONSHORE PHARMS	Methods and compositions for treatment of attention deficit disorder	Mar, 2032 (9 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

62. List of Korlym drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842801	CORCEPT THERAP	Optimizing mifepristone absorption	Nov, 2032 (9 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

63. List of Kuvan drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178	BIOMARIN PHARM	Dry blend formulation of tetrahydrobiopterin	Nov, 2032 (9 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: NA

Dosage: POWDER;ORAL

64. List of Lazanda drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731869	BTCP PHARMA	Container	Jan, 2032 (8 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: NA

Dosage: SPRAY, METERED;NASAL

65. List of Levothyroxine Sodium drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238	FRESENIUS KABI USA	Levothyroxine formulations	Aug, 2032 (9 years from now)
US9168239	FRESENIUS KABI USA	Levothyroxine formulations	Aug, 2032 (9 years from now)
US9006289	FRESENIUS KABI USA	Levothyroxine formulations	Oct, 2032 (9 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS

66. List of Livmarli drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376251	MIRUM	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases	Oct, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 29, 2026
Orphan Drug Exclusivity (ODE)	Sep 29, 2028

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

67. List of Lokelma drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11406662	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US10413569	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US8802152	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808750	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US9844567	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US9861658	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US10335432	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US10398730	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 18, 2023
M	Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

68. List of Lonhala Magnair Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168556	SUNOVION RESP	Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer	Sep, 2032 (9 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

69. List of Lybalvi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778960	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Feb, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain

Dosage: TABLET;ORAL

70. List of Mavyret drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037	ABBVIE INC	Macrocyclic proline derived HCV serine protease inhibitors	Jan, 2032 (8 years from now)
US8937150	ABBVIE INC	Anti-viral compounds	May, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648037 (Pediatric)	ABBVIE INC	Macrocyclic proline derived HCV serine protease inhibitors	Jul, 2032 (9 years from now)
US8937150 (Pediatric)	ABBVIE INC	Anti-viral compounds	Nov, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 3, 2022
M	Apr 10, 2023
New Dosing Schedule (D)	Sep 26, 2022
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
Pediatric Exclusivity (PED)	Mar 26, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: March, 2022

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: PELLETS;ORAL

71. List of Mekinist drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399021	NOVARTIS	Pharmaceutical composition	Jan, 2032 (8 years from now)
US9271941	NOVARTIS	Pharmaceutical composition	Jan, 2032 (8 years from now)
US9155706	NOVARTIS	Pharmaceutical composition	Jan, 2032 (8 years from now)
US8580304	NOVARTIS	Pharmaceutical composition	Jan, 2032 (8 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 22, 2024
M	Oct 6, 2022
New Indication (I)	Jun 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

72. List of Movantik drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012469	REDHILL	Crystalline naloxol-peg conjugate	Apr, 2032 (9 years from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: NA

Dosage: TABLET;ORAL

73. List of Neoprofen drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337	RECORDATI RARE	Ibuprofen compositions and methods of making same	Mar, 2032 (9 years from now)

Drugs and Companies using IBUPROFEN LYSINE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

74. List of Netspot drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375498	AAA USA INC	Process for the preparation of complexes of 68Ga	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 1, 2023

Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient

Market Authorisation Date: 01 June, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

75. List of Neupro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925150	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Mar, 2032 (9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

76. List of Nuvessa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198858	CHEMO RESEARCH SL	Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations	Jun, 2032 (9 years from now)
US8946276	CHEMO RESEARCH SL	High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis	Jun, 2032 (9 years from now)
US10596155	CHEMO RESEARCH SL	Aqueous-based metronidazole gel formulations	Jun, 2032 (9 years from now)
US10238634	CHEMO RESEARCH SL	Aqueous-based metronidazole gel formulations	Jun, 2032 (9 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 24 March, 2014

Treatment: Treatment of bacterial vaginosis with metronidazole gel

Dosage: GEL;VAGINAL

77. List of Odefsey drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

78. List of Ofirmev drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Mar, 2032 (9 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

79. List of Olinvyk drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11077098	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)
US9309234	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)
US8835488	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

80. List of Olumiant drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089574	ELI LILLY AND CO	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections	Nov, 2032 (9 years from now)
US11045474	ELI LILLY AND CO	Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections	Nov, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	May 10, 2025
New Chemical Entity Exclusivity (NCE)	May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo)

Dosage: TABLET;ORAL

81. List of Ongentys drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9630955	NEUROCRINE	Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor	Dec, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

82. List of Oxbryta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10034879	GLOBAL BLOOD THERAPS	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation	Dec, 2032 (9 years from now)
US10806733	GLOBAL BLOOD THERAPS	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation	Dec, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491	GLOBAL BLOOD THERAPS	Compounds and uses thereof for the modulation of hemoglobin	Dec, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

83. List of Ozempic drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Jan 16, 2023
New Chemical Entity Exclusivity (NCE)	Dec 5, 2022
New Dosing Schedule (D)	Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

84. List of Pataday Once Daily Relief drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791154	ALCON LABS INC	High concentration olopatadine ophthalmic composition	May, 2032 (9 years from now)
US9533053	ALCON LABS INC	High concentration olopatadine ophthalmic composition	May, 2032 (9 years from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

85. List of Pepaxto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285946	ONCOPEPTIDES AB	Lyophilized preparations of melphalan flufenamide	Apr, 2032 (9 years from now)
US11344622	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10543274	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10322182	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10869928	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Feb 26, 2028
New Chemical Entity Exclusivity (NCE)	Feb 26, 2026

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy

Dosage: POWDER;INTRAVENOUS

86. List of Plenvu drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529368	SALIX	Colonoscopy—preparation	Mar, 2032 (9 years from now)
US10780112	SALIX	Colonoscopy-preparation	Mar, 2032 (9 years from now)
US10792306	SALIX	Colonoscopy—preparation	Mar, 2032 (9 years from now)
US10646512	SALIX	Colonoscopy - preparation	Mar, 2032 (9 years from now)
US9592252	SALIX	Colonoscopy—preparation	Aug, 2032 (9 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 04 May, 2018

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

87. List of Ponvory drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9062014	JANSSEN PHARMS	Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one	May, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET;ORAL

88. List of Precedex drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338470	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US8455527	HOSPIRA	Methods of treatment using a dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US8648106	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US9616049	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US8242158	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US10016396	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US9320712	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (8 years from now)
US8455527 (Pediatric)	HOSPIRA	Methods of treatment using a dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8338470 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US9320712 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US9616049 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8242158 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8648106 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 December, 1999

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

89. List of Prezcobix drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	JANSSEN PRODS	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

90. List of Proair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (8 years from now)
US8978966	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

91. List of Proair Hfa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

92. List of Prolensa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085958	BAUSCH AND LOMB	Bromfenac bioavailability	Nov, 2032 (9 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

93. List of Pyrukynd drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US10632114	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9980961	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9193701	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	Oct, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency

Dosage: TABLET;ORAL

94. List of Qinlock drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461179	DECIPHERA PHARMS	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jun, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731	DECIPHERA PHARMS	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jun, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 15, 2025
Orphan Drug Exclusivity (ODE)	May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor

Dosage: TABLET;ORAL

95. List of Qulipta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096	ABBVIE INC	Piperidinone carboxamide azaindane CGRP receptor antagonists	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

96. List of Qvar 40 drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

97. List of Qvar Redihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	NORTON WATERFORD	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

98. List of Ravicti drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326966	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Mar, 2032 (9 years from now)
US8404215	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging	Mar, 2032 (9 years from now)
US9095559	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Mar, 2032 (9 years from now)
US9254278	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 28, 2024

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Market Authorisation Date: 01 February, 2013

Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID;ORAL

99. List of Restasis drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8561859	ALLERGAN	Dispensing device	Apr, 2032 (9 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

100. List of Rexulti drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307419	OTSUKA	Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof	Oct, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Dec 27, 2024

Drugs and Companies using BREXPIPRAZOLE ingredient

Market Authorisation Date: 10 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

101. List of Saxenda drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (9 years from now)
US9132239 (Pediatric)	NOVO	Dial-down mechanism for wind-up pen	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

102. List of Sinuva drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8763222	INTERSECT ENT INC	Methods and devices for crimping self-expanding devices	Feb, 2032 (9 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

103. List of Stivarga drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9957232	BAYER HLTHCARE	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 27, 2024

Drugs and Companies using REGORAFENIB ingredient

Market Authorisation Date: 27 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

104. List of Stribild drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 27 August, 2012

Treatment: NA

Dosage: TABLET;ORAL

105. List of Sublocade drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921387	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jan, 2032 (8 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treating opioid dependency by administering buprenorphine once per month; Treating opioid dependence by administering buprenorphine

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

106. List of Symtuza drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	JANSSEN PRODS	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	JANSSEN PRODS	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	JANSSEN PRODS	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months

Dosage: TABLET;ORAL

107. List of Synjardy Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120	BOEHRINGER INGELHEIM	Pharmaceutical compositions	Mar, 2032 (9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

108. List of Tagrisso drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11524951	ASTRAZENECA	2-(2,4,5-substituted-anilino)pyrimidine compounds	Jul, 2032 (9 years from now)
US9732058	ASTRAZENECA	2-(2,4,5-substituted-anilino)pyrimidine compounds	Jul, 2032 (9 years from now)
US8946235	ASTRAZENECA	2-(2,4,5-substituted-anilino) pyrimidine compounds	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 18, 2027
New Indication (I)	Dec 18, 2023

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

109. List of Tasigna drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061029	NOVARTIS	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9061029 (Pediatric)	NOVARTIS	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Oct, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 23, 2028
Pediatric Exclusivity (PED)	Sep 22, 2025

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2007

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation

Dosage: CAPSULE;ORAL

110. List of Tavalisse drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8771648	RIGEL PHARMS INC	(Trimethoxyphenylamino) pyrimidinyl formulations	Jul, 2032 (9 years from now)
US8951504	RIGEL PHARMS INC	(trimethoxyphenylamino) pyrimidinyl formulations	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 17, 2025
New Chemical Entity Exclusivity (NCE)	Apr 17, 2023

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 17 April, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

111. List of Tazverik drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11052093	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US9090562	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522152	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US9855275	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US8765732	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US10155002	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US9549931	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US10420775	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 23, 2025
New Indication (I)	Jun 18, 2023
Orphan Drug Exclusivity (ODE)	Jan 23, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma; Method of treating follicular lymphoma

Dosage: TABLET;ORAL

112. List of Technivie drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

113. List of Torisel drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791097	PF PRISM CV	Anti-tumor activity of CCI-779 in papillary renal cell cancer	May, 2032 (9 years from now)
US8791097 (Pediatric)	PF PRISM CV	Anti-tumor activity of CCI-779 in papillary renal cell cancer	Nov, 2032 (9 years from now)

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

114. List of Trijardy Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120	BOEHRINGER INGELHEIM	Pharmaceutical compositions	Mar, 2032 (9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin

Dosage: TABLET, EXTENDED RELEASE;ORAL

115. List of Trintellix drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278096	TAKEDA PHARMS USA	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity	Mar, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
M	Jan 22, 2024

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Market Authorisation Date: 30 September, 2013

Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

116. List of Trudhesa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036	IMPEL NEUROPHARMA	Nasal drug delivery device	Sep, 2032 (9 years from now)
US10507295	IMPEL NEUROPHARMA	Nasal drug delivery device	Dec, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: NA

Dosage: SPRAY, METERED;NASAL

117. List of Trulance drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11319346	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Mar, 2032 (9 years from now)
US9616097	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Aug, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: NA

Dosage: TABLET;ORAL

118. List of Tukysa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457093	SEAGEN	Solid dispersions of a ERB2 (HER2) inhibitor	Oct, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 17, 2027
New Chemical Entity Exclusivity (NCE)	Apr 17, 2025

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

119. List of Tuxarin Er drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066942	MAINPOINTE	Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer	Jan, 2032 (8 years from now)
US9107921	MAINPOINTE	Oral dosage forms for oxygen containing active agents and oxyl-containing polymers	Jan, 2032 (8 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE;ORAL

120. List of Tybost drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 22, 2026
New Patient Population (NPP)	Aug 22, 2022

Drugs and Companies using COBICISTAT ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: TABLET;ORAL

121. List of Ubrelvy drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096	ALLERGAN	Piperidinone carboxamide azaindane CGRP receptor antagonists	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with headache, with or without aura in adults

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.5MG;100MG	CAPSULE;ORAL	Prescription
1MG;100MG	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
EQ 30MG BASE;120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.1 mg/0.3 mg and 4.2 mg/0.7 mg	23 Nov, 2016	1		20 Aug, 2032
6.3 mg/1 mg	21 Dec, 2015	1		20 Aug, 2032

Strength	Dosage	Availability
EQ 2.1MG BASE;EQ 0.3MG BASE	FILM;BUCCAL	Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE	FILM;BUCCAL	Discontinued
EQ 6.3MG BASE;EQ 1MG BASE	FILM;BUCCAL	Discontinued

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 60MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
400MG/4ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
800MG/8ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
800MG/200ML (4MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription
70MG/VIAL	POWDER;INTRAVENOUS	Prescription

Strength	Dosage	Availability
2.5GM	TABLET, EFFERVESCENT;ORAL	Discontinued
500MG	TABLET, EFFERVESCENT;ORAL	Discontinued

Strength	Dosage	Availability
8.6MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
17.3MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
25.9MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
120 mg/15 mg	31 Oct, 2022	1		15 Aug, 2032
200 mg/25 mg	05 Nov, 2019	6		15 Aug, 2032

Strength	Dosage	Availability
120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
0.2MG/ML	INJECTABLE;INJECTION	Prescription
1MG/ML	INJECTABLE;INJECTION	Prescription
2MG/ML	INJECTABLE;INJECTION	Prescription
4MG/ML	INJECTABLE;INJECTION	Discontinued
10MG/ML	INJECTABLE;INJECTION	Discontinued
250MG/VIAL	INJECTABLE;INJECTION	Discontinued

Strength	Dosage	Availability
200MG;200MG	TABLET;ORAL	Discontinued
300MG;200MG	TABLET;ORAL	Discontinued

Strength	Dosage	Availability
150MG;37.5MG/PACKET	PELLETS;ORAL	Prescription
200MG;50MG/PACKET	PELLETS;ORAL	Prescription

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 40MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 80MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 120MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
EQ 80MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription
EQ 120MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.5 mg	22 Sep, 2014	19	04 Dec, 2019	29 Mar, 2026	Deferred
0.25 mg	19 Jul, 2018	1	12 Nov, 2021	30 Mar, 2032	Eligible

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
45MG;200MG	TABLET;ORAL	Prescription
90MG;400MG	TABLET;ORAL	Prescription

Pharsight

Drug Patents Expiring in 2032

1. List of Abilify Mycite Kit drug patents

2. List of Abraxane drug patents

3. List of Acetadote drug patents

4. List of Adzenys Er drug patents

5. List of Adzenys Xr-odt drug patents

6. List of Airduo Digihaler drug patents

7. List of Akynzeo drug patents

8. List of Alecensa drug patents

9. List of Aliqopa drug patents

10. List of Alkindi Sprinkle drug patents

11. List of Amvuttra drug patents

12. List of Aptiom drug patents

13. List of Aristada drug patents

14. List of Armonair Digihaler drug patents

15. List of Avycaz drug patents

16. List of Azstarys drug patents

17. List of Belbuca drug patents

18. List of Bijuva drug patents

19. List of Bijuva drug patents

20. List of Biktarvy drug patents

21. List of Bortezomib drug patents

22. List of Braftovi drug patents

23. List of Bunavail drug patents

24. List of Cabometyx drug patents

25. List of Caldolor drug patents

26. List of Calquence drug patents

27. List of Calquence drug patents

28. List of Caspofungin Acetate drug patents

29. List of Cetylev drug patents

30. List of Cometriq drug patents

31. List of Contrave drug patents

32. List of Copiktra drug patents

33. List of Cotempla Xr-odt drug patents

34. List of Cycloset drug patents

35. List of Defitelio drug patents

36. List of Descovy drug patents

37. List of Detectnet drug patents

38. List of Dexilant drug patents

39. List of Dexycu Kit drug patents

40. List of Dilaudid drug patents

41. List of Duzallo drug patents

42. List of Epaned Kit drug patents

43. List of Epclusa drug patents

44. List of Epsolay drug patents

45. List of Evotaz drug patents

46. List of Evzio drug patents

47. List of Evzio (autoinjector) drug patents

48. List of Fetzima drug patents

49. List of Firdapse drug patents

50. List of Firmagon drug patents

51. List of Genvoya drug patents

52. List of Gilenya drug patents

53. List of Gonitro drug patents

54. List of Harvoni drug patents

55. List of Ilevro drug patents

56. List of Imvexxy drug patents

57. List of Inbrija drug patents

58. List of Inrebic drug patents

59. List of Ionsys drug patents

60. List of Isentress drug patents

61. List of Jornay Pm drug patents

62. List of Korlym drug patents

63. List of Kuvan drug patents

64. List of Lazanda drug patents

65. List of Levothyroxine Sodium drug patents

66. List of Livmarli drug patents

67. List of Lokelma drug patents

68. List of Lonhala Magnair Kit drug patents

69. List of Lybalvi drug patents

70. List of Mavyret drug patents

71. List of Mekinist drug patents

72. List of Movantik drug patents

73. List of Neoprofen drug patents

74. List of Netspot drug patents

75. List of Neupro drug patents

76. List of Nuvessa drug patents

77. List of Odefsey drug patents

78. List of Ofirmev drug patents

Strength	Dosage	Availability
0.004MG	INSERT;VAGINAL	Prescription
0.01MG	INSERT;VAGINAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
400 mg	12 Oct, 2011	1		11 Mar, 2029
600 mg	21 Oct, 2022	1		30 Mar, 2032

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg	05 Jun, 2014	1	10 May, 2019	16 Nov, 2025	Eligible
100 mg per packet	09 Nov, 2015	1	20 Aug, 2019	17 May, 2025	Eligible Deferred
500 mg per packet	23 Feb, 2017	1	20 Aug, 2019	01 Nov, 2032	Eligible

Strength	Dosage	Availability
100MG/PACKET	POWDER;ORAL	Prescription
500MG/PACKET	POWDER;ORAL	Prescription

Strength	Dosage	Availability
EQ 0.1MG BASE	SPRAY, METERED;NASAL	Prescription
EQ 0.3MG BASE	SPRAY, METERED;NASAL	Discontinued
EQ 0.4MG BASE	SPRAY, METERED;NASAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mcg/vial and 500 mcg/vial	14 Apr, 2015	2	29 Jun, 2016	03 Oct, 2032	Eligible
200 mcg/vial	01 May, 2015	1	07 Dec, 2015	03 Oct, 2032	Deferred

Strength	Dosage	Availability
100MCG/VIAL	POWDER;INTRAVENOUS	Prescription
200MCG/VIAL	POWDER;INTRAVENOUS	Prescription
500MCG/VIAL	POWDER;INTRAVENOUS	Prescription

Strength	Dosage	Availability
5GM/PACKET	FOR SUSPENSION;ORAL	Prescription
10GM/PACKET	FOR SUSPENSION;ORAL	Prescription

Strength	Dosage	Availability
5MG;EQ 10MG BASE	TABLET;ORAL	Prescription
10MG;EQ 10MG BASE	TABLET;ORAL	Prescription
15MG;EQ 10MG BASE	TABLET;ORAL	Prescription
20MG;EQ 10MG BASE	TABLET;ORAL	Prescription